Jauregui-Amezaga Aranzazu, Somers Michael, De Schepper Heiko, Macken Elisabeth
Department of Gastroenterology, Universitair Ziekenhuis Antwerpen, University of Antwerp, Antwerp, Belgium.
Clin Exp Gastroenterol. 2017 Nov 15;10:293-301. doi: 10.2147/CEG.S110546. eCollection 2017.
The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn's disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit of the cytokines interleukin-12 as well as interleukin-23. Consequently, the Th1 and Th17 inflammatory responses are inhibited. Ustekinumab has been recently approved for its use in patients with Crohn's disease. Its efficacy and safety was initially proved in patients with psoriasis and psoriatic arthritis. More recently, three Phase III trials have confirmed its efficacy in patients with Crohn's disease refractory to anti-tumor necrosis factor therapy. This biologic agent appears safe, with no increased risk of infectious or malignant complications, and a low immunogenic profile.
目前可用的药物疗法对一部分克罗恩病患者疗效有限，这促使人们研发能够阻断新炎症通路的分子。优特克单抗是一种全人源IgG1单克隆抗体，它作用于细胞因子白细胞介素-12以及白细胞介素-23的共同p40亚基。因此，Th1和Th17炎症反应受到抑制。优特克单抗最近已获批用于克罗恩病患者。其疗效和安全性最初在银屑病和银屑病关节炎患者中得到证实。最近，三项III期试验证实了其在对抗肿瘤坏死因子治疗无效的克罗恩病患者中的疗效。这种生物制剂似乎是安全的，没有增加感染或恶性并发症的风险，且免疫原性较低。
